Company
Headquarters: Auckland, New Zealand
CEO: Dr. Brian Ward
A$271.3 Million
AUD as of Jan. 1, 2024
US$184.8 Million
Company | Market Cap (USD) |
---|---|
Abbott | $192.67 B |
Stryker Corporation | $113.24 B |
Medtronic | $111.60 B |
Boston Scientific Corporation | $85.22 B |
Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and selling of medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobia for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. The company was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Aroa Biosurgery Limited has the following listings and related stock indices.
Stock: ASX: ARX wb_incandescent